| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vancomycin | 13 | 2025 | 236 | 4.520 |
Why?
|
| Anticoagulants | 15 | 2022 | 628 | 3.070 |
Why?
|
| Anti-Bacterial Agents | 20 | 2025 | 2575 | 2.880 |
Why?
|
| Acute Kidney Injury | 13 | 2025 | 706 | 2.440 |
Why?
|
| Intensive Care Units, Pediatric | 18 | 2024 | 485 | 2.240 |
Why?
|
| Anti-Arrhythmia Agents | 10 | 2021 | 227 | 2.120 |
Why?
|
| Gentamicins | 7 | 2018 | 96 | 2.080 |
Why?
|
| Heart Defects, Congenital | 20 | 2019 | 1887 | 2.030 |
Why?
|
| Retrospective Studies | 87 | 2025 | 17568 | 1.950 |
Why?
|
| Infant | 72 | 2025 | 13243 | 1.930 |
Why?
|
| Warfarin | 7 | 2015 | 134 | 1.870 |
Why?
|
| Child, Preschool | 75 | 2025 | 14873 | 1.850 |
Why?
|
| Enoxaparin | 4 | 2017 | 49 | 1.650 |
Why?
|
| Antithrombins | 4 | 2019 | 61 | 1.620 |
Why?
|
| Infant, Newborn | 52 | 2022 | 8632 | 1.600 |
Why?
|
| Child | 85 | 2025 | 25868 | 1.560 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2019 | 1714 | 1.500 |
Why?
|
| Diuretics | 7 | 2018 | 168 | 1.430 |
Why?
|
| Critical Illness | 9 | 2024 | 629 | 1.420 |
Why?
|
| Heparin | 7 | 2022 | 230 | 1.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2014 | 225 | 1.390 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2021 | 475 | 1.340 |
Why?
|
| Digoxin | 3 | 2015 | 43 | 1.310 |
Why?
|
| Obesity | 9 | 2018 | 2440 | 1.310 |
Why?
|
| Drug Monitoring | 7 | 2017 | 185 | 1.300 |
Why?
|
| Male | 102 | 2025 | 65592 | 1.290 |
Why?
|
| Adolescent | 63 | 2025 | 20573 | 1.250 |
Why?
|
| Hospitals, Pediatric | 11 | 2019 | 795 | 1.230 |
Why?
|
| Phenobarbital | 2 | 2019 | 35 | 1.200 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 90 | 1.180 |
Why?
|
| Female | 99 | 2025 | 71503 | 1.140 |
Why?
|
| Cardiac Surgical Procedures | 12 | 2019 | 1163 | 1.110 |
Why?
|
| Heart-Assist Devices | 7 | 2020 | 1098 | 1.110 |
Why?
|
| Phenytoin | 2 | 2018 | 63 | 1.060 |
Why?
|
| Humans | 131 | 2025 | 133373 | 1.050 |
Why?
|
| Vasodilator Agents | 4 | 2015 | 213 | 1.030 |
Why?
|
| Heart Diseases | 4 | 2017 | 519 | 1.020 |
Why?
|
| Heart Failure | 12 | 2016 | 2428 | 0.980 |
Why?
|
| Potassium | 3 | 2017 | 278 | 0.950 |
Why?
|
| Tachycardia, Supraventricular | 4 | 2014 | 110 | 0.920 |
Why?
|
| Critical Care | 5 | 2017 | 698 | 0.890 |
Why?
|
| Furosemide | 4 | 2018 | 37 | 0.880 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2020 | 648 | 0.870 |
Why?
|
| Acetaminophen | 3 | 2019 | 102 | 0.860 |
Why?
|
| Anti-Infective Agents | 3 | 2021 | 276 | 0.850 |
Why?
|
| Antihypertensive Agents | 3 | 2016 | 410 | 0.820 |
Why?
|
| Medication Adherence | 2 | 2018 | 343 | 0.820 |
Why?
|
| Cardiotonic Agents | 6 | 2014 | 144 | 0.800 |
Why?
|
| Seizures | 2 | 2018 | 889 | 0.800 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2021 | 772 | 0.790 |
Why?
|
| Kidney | 4 | 2018 | 1395 | 0.790 |
Why?
|
| Creatinine | 14 | 2022 | 418 | 0.780 |
Why?
|
| Length of Stay | 8 | 2019 | 1393 | 0.770 |
Why?
|
| Drug Utilization | 2 | 2021 | 169 | 0.760 |
Why?
|
| Diuresis | 4 | 2017 | 58 | 0.740 |
Why?
|
| Texas | 19 | 2021 | 3666 | 0.730 |
Why?
|
| Patient Readmission | 3 | 2016 | 430 | 0.720 |
Why?
|
| Near Drowning | 1 | 2021 | 26 | 0.690 |
Why?
|
| Patient Admission | 4 | 2016 | 191 | 0.670 |
Why?
|
| Drowning | 1 | 2021 | 47 | 0.660 |
Why?
|
| Antithrombin III | 2 | 2017 | 28 | 0.660 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 89 | 0.660 |
Why?
|
| Databases, Factual | 10 | 2020 | 1240 | 0.650 |
Why?
|
| Metabolic Clearance Rate | 6 | 2019 | 143 | 0.640 |
Why?
|
| Ketorolac | 2 | 2012 | 13 | 0.640 |
Why?
|
| Nitroprusside | 3 | 2011 | 42 | 0.640 |
Why?
|
| Infusions, Intravenous | 9 | 2018 | 569 | 0.640 |
Why?
|
| Antipyretics | 1 | 2019 | 8 | 0.630 |
Why?
|
| Natriuretic Agents | 4 | 2007 | 33 | 0.620 |
Why?
|
| Body Weight | 9 | 2022 | 1035 | 0.620 |
Why?
|
| Flecainide | 2 | 2021 | 23 | 0.620 |
Why?
|
| Propensity Score | 2 | 2018 | 263 | 0.620 |
Why?
|
| Ibuprofen | 1 | 2019 | 42 | 0.620 |
Why?
|
| Area Under Curve | 4 | 2024 | 330 | 0.610 |
Why?
|
| Ciprofloxacin | 2 | 2013 | 69 | 0.600 |
Why?
|
| Body Temperature | 1 | 2019 | 128 | 0.600 |
Why?
|
| Models, Biological | 4 | 2021 | 1531 | 0.590 |
Why?
|
| Health Information Systems | 2 | 2020 | 35 | 0.590 |
Why?
|
| Heart Rate | 7 | 2018 | 586 | 0.590 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 4 | 0.590 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 25 | 0.590 |
Why?
|
| Enalapril | 3 | 2014 | 14 | 0.580 |
Why?
|
| Hyperkalemia | 2 | 2017 | 71 | 0.580 |
Why?
|
| Alprostadil | 2 | 2015 | 26 | 0.580 |
Why?
|
| Age Factors | 10 | 2019 | 2956 | 0.570 |
Why?
|
| Risk Factors | 22 | 2025 | 10954 | 0.560 |
Why?
|
| Fenoldopam | 2 | 2008 | 9 | 0.560 |
Why?
|
| Drug Interactions | 5 | 2021 | 259 | 0.560 |
Why?
|
| International Normalized Ratio | 4 | 2013 | 45 | 0.550 |
Why?
|
| Blood Pressure | 7 | 2019 | 1411 | 0.550 |
Why?
|
| Pediatrics | 6 | 2022 | 1221 | 0.540 |
Why?
|
| Hospitalization | 7 | 2018 | 1921 | 0.540 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 313 | 0.540 |
Why?
|
| Hypertension | 3 | 2016 | 1403 | 0.540 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 314 | 0.540 |
Why?
|
| Propranolol | 2 | 2014 | 121 | 0.540 |
Why?
|
| Spironolactone | 1 | 2017 | 20 | 0.540 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 209 | 0.530 |
Why?
|
| Hypotension | 5 | 2019 | 188 | 0.530 |
Why?
|
| Postoperative Complications | 8 | 2019 | 3171 | 0.530 |
Why?
|
| Sotalol | 2 | 2021 | 34 | 0.530 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.530 |
Why?
|
| Nephrons | 1 | 2016 | 19 | 0.530 |
Why?
|
| Thromboembolism | 1 | 2017 | 93 | 0.520 |
Why?
|
| Hypokalemia | 2 | 2017 | 41 | 0.520 |
Why?
|
| Hospital Mortality | 8 | 2022 | 1100 | 0.520 |
Why?
|
| Amiodarone | 2 | 2015 | 46 | 0.520 |
Why?
|
| Cation Exchange Resins | 1 | 2016 | 2 | 0.510 |
Why?
|
| Dexmedetomidine | 2 | 2014 | 50 | 0.510 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2007 | 343 | 0.510 |
Why?
|
| Polystyrenes | 1 | 2016 | 12 | 0.510 |
Why?
|
| Infusions, Parenteral | 2 | 2014 | 97 | 0.510 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2014 | 251 | 0.510 |
Why?
|
| Time Factors | 15 | 2019 | 6544 | 0.500 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 573 | 0.500 |
Why?
|
| Treatment Outcome | 25 | 2020 | 13103 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2014 | 288 | 0.500 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.490 |
Why?
|
| Hypnotics and Sedatives | 2 | 2014 | 138 | 0.490 |
Why?
|
| Fractures, Bone | 1 | 2018 | 211 | 0.490 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 122 | 0.470 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 279 | 0.470 |
Why?
|
| Overweight | 2 | 2015 | 386 | 0.460 |
Why?
|
| Acetazolamide | 3 | 2018 | 32 | 0.450 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 1463 | 0.450 |
Why?
|
| Aortic Coarctation | 1 | 2016 | 108 | 0.450 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 563 | 0.450 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 237 | 0.450 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 336 | 0.440 |
Why?
|
| Thrombosis | 3 | 2015 | 545 | 0.440 |
Why?
|
| Incidence | 12 | 2019 | 3395 | 0.440 |
Why?
|
| Young Adult | 16 | 2020 | 9923 | 0.430 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 835 | 0.420 |
Why?
|
| Case-Control Studies | 10 | 2018 | 3418 | 0.420 |
Why?
|
| Body Mass Index | 3 | 2015 | 1713 | 0.420 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 151 | 0.420 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 173 | 0.420 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 74 | 0.420 |
Why?
|
| Cohort Studies | 12 | 2025 | 5199 | 0.410 |
Why?
|
| Immunologic Factors | 1 | 2014 | 186 | 0.400 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 46 | 0.400 |
Why?
|
| Administration, Oral | 5 | 2018 | 719 | 0.400 |
Why?
|
| Cyanides | 2 | 2009 | 9 | 0.400 |
Why?
|
| Cardiomyopathies | 3 | 2014 | 510 | 0.400 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 190 | 0.400 |
Why?
|
| Potassium Chloride | 1 | 2012 | 55 | 0.400 |
Why?
|
| Anticonvulsants | 1 | 2015 | 396 | 0.390 |
Why?
|
| Medical Audit | 1 | 2013 | 104 | 0.390 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 84 | 0.390 |
Why?
|
| Anesthetics | 1 | 2012 | 78 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2014 | 232 | 0.360 |
Why?
|
| Linear Models | 6 | 2017 | 719 | 0.360 |
Why?
|
| Anesthesiology | 1 | 2012 | 99 | 0.350 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 273 | 0.340 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2011 | 109 | 0.340 |
Why?
|
| Blood Coagulation | 1 | 2011 | 134 | 0.340 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2012 | 148 | 0.340 |
Why?
|
| Drug Dosage Calculations | 3 | 2013 | 23 | 0.330 |
Why?
|
| Guideline Adherence | 1 | 2013 | 395 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 5443 | 0.330 |
Why?
|
| Logistic Models | 5 | 2018 | 1864 | 0.320 |
Why?
|
| Anesthesia | 1 | 2012 | 212 | 0.320 |
Why?
|
| Tertiary Care Centers | 4 | 2019 | 271 | 0.320 |
Why?
|
| United States | 11 | 2019 | 11722 | 0.320 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 269 | 0.310 |
Why?
|
| Cardiology | 1 | 2014 | 521 | 0.290 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 669 | 0.290 |
Why?
|
| Dopamine Agonists | 1 | 2008 | 80 | 0.280 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2018 | 15 | 0.280 |
Why?
|
| Pharmacy | 1 | 2007 | 20 | 0.280 |
Why?
|
| Alkalosis | 1 | 2007 | 24 | 0.270 |
Why?
|
| Purines | 2 | 2018 | 119 | 0.270 |
Why?
|
| Chlorides | 1 | 2007 | 108 | 0.270 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2007 | 29 | 0.270 |
Why?
|
| Procainamide | 1 | 2006 | 4 | 0.270 |
Why?
|
| Half-Life | 3 | 2019 | 162 | 0.270 |
Why?
|
| Oliguria | 1 | 2006 | 20 | 0.260 |
Why?
|
| Heart Ventricles | 1 | 2011 | 789 | 0.250 |
Why?
|
| Intensive Care Units | 3 | 2021 | 542 | 0.250 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2006 | 40 | 0.250 |
Why?
|
| Heart Transplantation | 7 | 2020 | 887 | 0.250 |
Why?
|
| Emergency Service, Hospital | 4 | 2018 | 1166 | 0.250 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2006 | 33 | 0.250 |
Why?
|
| Adult | 19 | 2022 | 31684 | 0.250 |
Why?
|
| Kidney Diseases | 4 | 2014 | 494 | 0.240 |
Why?
|
| Acute Disease | 4 | 2018 | 1184 | 0.240 |
Why?
|
| Factor Xa | 2 | 2017 | 19 | 0.240 |
Why?
|
| Administration, Intravenous | 3 | 2025 | 162 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 256 | 0.230 |
Why?
|
| Shock, Septic | 1 | 2006 | 157 | 0.230 |
Why?
|
| Vomiting | 2 | 2016 | 110 | 0.230 |
Why?
|
| Pyrazoles | 2 | 2018 | 334 | 0.230 |
Why?
|
| Captopril | 3 | 2014 | 26 | 0.220 |
Why?
|
| Coronary Care Units | 3 | 2016 | 38 | 0.220 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 221 | 0.220 |
Why?
|
| Nausea | 2 | 2015 | 87 | 0.220 |
Why?
|
| Referral and Consultation | 1 | 2007 | 574 | 0.210 |
Why?
|
| Injections, Intravenous | 2 | 2016 | 251 | 0.210 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 501 | 0.210 |
Why?
|
| Electrocardiography | 4 | 2015 | 997 | 0.200 |
Why?
|
| Paraspinal Muscles | 1 | 2022 | 9 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 1165 | 0.200 |
Why?
|
| Blood Urea Nitrogen | 4 | 2006 | 76 | 0.190 |
Why?
|
| Hemodynamics | 5 | 2018 | 858 | 0.190 |
Why?
|
| Busulfan | 1 | 2021 | 45 | 0.180 |
Why?
|
| Nerve Block | 1 | 2022 | 67 | 0.180 |
Why?
|
| Residence Characteristics | 3 | 2021 | 290 | 0.180 |
Why?
|
| Double Outlet Right Ventricle | 2 | 2011 | 23 | 0.180 |
Why?
|
| Amoxicillin | 1 | 2021 | 117 | 0.170 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 2092 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2016 | 521 | 0.170 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 159 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2003 | 266 | 0.170 |
Why?
|
| Ireland | 1 | 2020 | 34 | 0.170 |
Why?
|
| Germany | 1 | 2020 | 60 | 0.170 |
Why?
|
| Myocarditis | 2 | 2013 | 133 | 0.170 |
Why?
|
| Computer Simulation | 2 | 2022 | 708 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 3 | 2022 | 69 | 0.160 |
Why?
|
| Respiratory Paralysis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 42 | 0.160 |
Why?
|
| Outpatients | 1 | 2021 | 275 | 0.160 |
Why?
|
| Weight Gain | 2 | 2013 | 412 | 0.160 |
Why?
|
| Drug Overdose | 2 | 2013 | 75 | 0.160 |
Why?
|
| Gestational Age | 2 | 2018 | 1231 | 0.160 |
Why?
|
| Asthma | 2 | 2017 | 807 | 0.160 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 17 | 0.160 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2013 | 272 | 0.150 |
Why?
|
| Nafcillin | 1 | 2018 | 14 | 0.150 |
Why?
|
| Diaphragm | 1 | 2019 | 99 | 0.150 |
Why?
|
| Clindamycin | 1 | 2018 | 42 | 0.150 |
Why?
|
| Drug Evaluation | 1 | 2018 | 105 | 0.150 |
Why?
|
| Hospital Costs | 2 | 2019 | 187 | 0.150 |
Why?
|
| Bupivacaine | 1 | 2018 | 29 | 0.150 |
Why?
|
| Hematocrit | 1 | 2018 | 116 | 0.150 |
Why?
|
| Serum Albumin | 1 | 2018 | 115 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 446 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 81 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 593 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 202 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 58 | 0.140 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 26 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 319 | 0.140 |
Why?
|
| Metolazone | 1 | 2017 | 5 | 0.140 |
Why?
|
| Syringes | 1 | 2017 | 25 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2018 | 66 | 0.140 |
Why?
|
| Conscious Sedation | 1 | 2018 | 62 | 0.140 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 181 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 53 | 0.140 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 27 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2018 | 49 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 90 | 0.140 |
Why?
|
| Peptide Fragments | 2 | 2014 | 828 | 0.140 |
Why?
|
| Spinal Fusion | 1 | 2018 | 115 | 0.140 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 150 | 0.130 |
Why?
|
| Drug Utilization Review | 2 | 2014 | 33 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2014 | 519 | 0.130 |
Why?
|
| Mitral Valve | 1 | 2019 | 270 | 0.130 |
Why?
|
| Fever | 1 | 2019 | 312 | 0.130 |
Why?
|
| Body Composition | 1 | 2019 | 563 | 0.130 |
Why?
|
| Epinephrine | 1 | 2017 | 176 | 0.130 |
Why?
|
| Kidney Function Tests | 2 | 2008 | 132 | 0.130 |
Why?
|
| Hirudins | 2 | 2014 | 40 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 230 | 0.130 |
Why?
|
| Administration, Rectal | 1 | 2016 | 8 | 0.130 |
Why?
|
| Azithromycin | 1 | 2016 | 46 | 0.130 |
Why?
|
| Software | 2 | 2021 | 732 | 0.130 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 66 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 55 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1033 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 66 | 0.120 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2019 | 467 | 0.120 |
Why?
|
| Solubility | 1 | 2015 | 140 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3869 | 0.120 |
Why?
|
| Air Pollutants | 1 | 2017 | 115 | 0.120 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 413 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2011 | 415 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1473 | 0.120 |
Why?
|
| Thinness | 1 | 2015 | 79 | 0.120 |
Why?
|
| Analgesics | 1 | 2016 | 131 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 683 | 0.120 |
Why?
|
| Allergens | 1 | 2017 | 279 | 0.110 |
Why?
|
| Institutional Practice | 1 | 2014 | 6 | 0.110 |
Why?
|
| Morbidity | 1 | 2015 | 255 | 0.110 |
Why?
|
| Pipecolic Acids | 1 | 2014 | 8 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 153 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 247 | 0.110 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 13 | 0.110 |
Why?
|
| Pharmaceutical Solutions | 1 | 2014 | 11 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 542 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 460 | 0.110 |
Why?
|
| Tablets | 1 | 2014 | 36 | 0.110 |
Why?
|
| Drug Compounding | 1 | 2014 | 43 | 0.110 |
Why?
|
| Databases as Topic | 1 | 2014 | 77 | 0.110 |
Why?
|
| Biological Availability | 1 | 2014 | 151 | 0.110 |
Why?
|
| Postoperative Care | 2 | 2013 | 311 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 93 | 0.110 |
Why?
|
| Diarrhea | 1 | 2016 | 339 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 164 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1340 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2017 | 252 | 0.110 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 57 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 343 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 54 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 543 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 262 | 0.110 |
Why?
|
| Infant, Premature | 4 | 2014 | 858 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2019 | 3718 | 0.100 |
Why?
|
| Chylothorax | 1 | 2013 | 29 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 469 | 0.100 |
Why?
|
| Anorexia | 1 | 2013 | 23 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 748 | 0.100 |
Why?
|
| Medical Records | 2 | 2011 | 194 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2013 | 32 | 0.100 |
Why?
|
| Citalopram | 1 | 2013 | 30 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1191 | 0.100 |
Why?
|
| Aspirin | 2 | 2012 | 231 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 245 | 0.100 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 42 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2013 | 104 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 332 | 0.100 |
Why?
|
| Levofloxacin | 1 | 2013 | 48 | 0.100 |
Why?
|
| Nutritional Support | 1 | 2013 | 57 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 1433 | 0.100 |
Why?
|
| Fasting | 1 | 2014 | 308 | 0.100 |
Why?
|
| Medicaid | 1 | 2015 | 254 | 0.100 |
Why?
|
| Age of Onset | 1 | 2014 | 628 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 216 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2014 | 289 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2012 | 93 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 244 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2016 | 376 | 0.090 |
Why?
|
| Arginine | 1 | 2014 | 350 | 0.090 |
Why?
|
| Patient Care | 1 | 2012 | 101 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 180 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 983 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 294 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 138 | 0.090 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2011 | 14 | 0.090 |
Why?
|
| Contraindications | 1 | 2011 | 77 | 0.090 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2011 | 62 | 0.090 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 701 | 0.090 |
Why?
|
| Ventilator Weaning | 1 | 2011 | 27 | 0.090 |
Why?
|
| Labetalol | 1 | 2011 | 12 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2013 | 179 | 0.090 |
Why?
|
| Serum | 1 | 2011 | 46 | 0.090 |
Why?
|
| Palliative Care | 2 | 2013 | 465 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2024 | 6582 | 0.090 |
Why?
|
| Tobramycin | 1 | 2010 | 23 | 0.080 |
Why?
|
| Sex Factors | 1 | 2014 | 1353 | 0.080 |
Why?
|
| Amikacin | 1 | 2010 | 27 | 0.080 |
Why?
|
| Hydrocortisone | 2 | 2014 | 246 | 0.080 |
Why?
|
| Fontan Procedure | 1 | 2012 | 191 | 0.080 |
Why?
|
| Biomarkers | 4 | 2014 | 3415 | 0.080 |
Why?
|
| Reoperation | 1 | 2013 | 853 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 384 | 0.080 |
Why?
|
| Thiocyanates | 1 | 2009 | 8 | 0.080 |
Why?
|
| Nitric Oxide Donors | 1 | 2009 | 21 | 0.080 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2011 | 199 | 0.080 |
Why?
|
| Methemoglobinemia | 1 | 2009 | 10 | 0.080 |
Why?
|
| Dopamine | 2 | 2014 | 285 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 1254 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2013 | 329 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2010 | 184 | 0.080 |
Why?
|
| Prognosis | 3 | 2014 | 5044 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 2 | 2022 | 50 | 0.080 |
Why?
|
| Acid-Base Imbalance | 1 | 2008 | 26 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2011 | 248 | 0.070 |
Why?
|
| Acidosis | 1 | 2009 | 102 | 0.070 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2008 | 19 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 523 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2011 | 488 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2006 | 213 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 806 | 0.070 |
Why?
|
| Acecainide | 1 | 2006 | 2 | 0.070 |
Why?
|
| Sodium Bicarbonate | 1 | 2007 | 57 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2007 | 88 | 0.070 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 2006 | 14 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 30 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2010 | 566 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2008 | 227 | 0.060 |
Why?
|
| Milrinone | 1 | 2006 | 31 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 376 | 0.060 |
Why?
|
| Medical Errors | 1 | 2006 | 160 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 910 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 1469 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 314 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2021 | 804 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 809 | 0.050 |
Why?
|
| Heart | 2 | 2018 | 712 | 0.050 |
Why?
|
| Pharmacokinetics | 1 | 2021 | 16 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2021 | 153 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 474 | 0.040 |
Why?
|
| Agriculture | 1 | 2001 | 33 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2019 | 18 | 0.040 |
Why?
|
| Women's Health | 1 | 2001 | 150 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 3105 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2992 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 441 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 782 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1469 | 0.030 |
Why?
|
| Liposomes | 1 | 2018 | 207 | 0.030 |
Why?
|
| Ozone | 1 | 2017 | 20 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2001 | 395 | 0.030 |
Why?
|
| Documentation | 1 | 2018 | 122 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 365 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 91 | 0.030 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 136 | 0.030 |
Why?
|
| Air Pollution | 1 | 2017 | 75 | 0.030 |
Why?
|
| Particulate Matter | 1 | 2017 | 80 | 0.030 |
Why?
|
| Penicillins | 1 | 2016 | 153 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2016 | 143 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 81 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 241 | 0.030 |
Why?
|
| Exercise Test | 1 | 2016 | 262 | 0.030 |
Why?
|
| Middle Aged | 2 | 2014 | 28985 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2014 | 8 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 149 | 0.030 |
Why?
|
| Vasopressins | 1 | 2014 | 45 | 0.030 |
Why?
|
| Dobutamine | 1 | 2014 | 58 | 0.030 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2014 | 42 | 0.030 |
Why?
|
| Thoracic Duct | 1 | 2013 | 6 | 0.030 |
Why?
|
| Pleurodesis | 1 | 2013 | 16 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 25 | 0.030 |
Why?
|
| Meningitis | 1 | 2014 | 101 | 0.030 |
Why?
|
| Bradycardia | 1 | 2014 | 62 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 171 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 823 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 134 | 0.030 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 113 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 13 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2013 | 69 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1584 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3740 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 333 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2014 | 192 | 0.020 |
Why?
|
| Candida | 1 | 2013 | 84 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2014 | 255 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 679 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 54 | 0.020 |
Why?
|
| Heterotaxy Syndrome | 1 | 2012 | 64 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2013 | 367 | 0.020 |
Why?
|
| Nicardipine | 1 | 2011 | 17 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 134 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1310 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 384 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 482 | 0.020 |
Why?
|
| Renin | 1 | 2007 | 88 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Aldosterone | 1 | 2007 | 67 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2007 | 174 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2008 | 162 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1583 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1622 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2010 | 685 | 0.020 |
Why?
|
| Electrolytes | 1 | 2006 | 55 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 133 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2207 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 245 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2632 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2006 | 527 | 0.010 |
Why?
|
| Aging | 1 | 2010 | 1280 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2288 | 0.010 |
Why?
|
| Stents | 1 | 2008 | 881 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 3043 | 0.010 |
Why?
|
| Louisiana | 1 | 2001 | 137 | 0.010 |
Why?
|
| Aged | 1 | 2001 | 21500 | 0.000 |
Why?
|